Literature DB >> 23979987

Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer.

Naoki Ozeki1, Takayuki Fukui, Tetsuo Taniguchi, Noriyasu Usami, Koji Kawaguchi, Simon Ito, Yukinori Sakao, Tetsuya Mitsudomi, Akihiro Hirakawa, Kohei Yokoi.   

Abstract

OBJECTIVES: The purpose of this study was to elucidate the detectability of recurrence and the prognostic significance of the serum carcinoembryonic antigen (CEA) levels in patients with completely resected non-small-cell lung cancer (NSCLC).
METHODS: Five hundred and eighteen NSCLC patients who underwent complete resection at Aichi Cancer Center between April 2001 and March 2006 were enrolled in this study. The patient characteristics were as follows: the median age was 63 years; 331 tumours were classified as pathological stage I, 88 tumours were pathological stage II and 99 tumours were pathological stage III; 140 tumours were adenocarcinomas with epidermal growth factor receptor (EGFR) mutations, 268 tumours were adenocarcinomas with EGFR wild-type mutations and 110 tumours were other NSCLCs. The patients were divided into three groups: those with a normal CEA level before and 1-3 months after surgery (N group, n = 380), those with an elevated CEA level before surgery and a normal CEA level 1-3 months after surgery (HN group, n = 105) and those with an elevated CEA level 1-3 months after surgery regardless of the preoperative CEA level (H group, n = 33). The correlations between the changes in the serum CEA levels and the clinical outcomes were analysed.
RESULTS: Recurrence developed in 122 patients (32%) in the N group, 49 patients (47%) in the HN group and 19 patients (58%) in the H group (P = 0.001). The sensitivity and specificity of an elevated serum CEA level during the follow-up period for detecting recurrence were 30 and 98% in the N group and 82 and 73% in the HN group, respectively. Twenty-seven asymptomatic recurrent tumours combined with an elevated serum CEA level were detected in the HN group. In the multivariate Cox regression analysis, the serum CEA level 1-3 months after surgery had prognostic value for overall survival.
CONCLUSIONS: In completely resected NSCLC patients, measuring the serum CEA level during the follow-up period is useful in patients in whom an elevated level normalizes after surgery, and the serum CEA level 1-3 months after surgery is considered to have prognostic significance regarding survival.

Entities:  

Keywords:  Carcinoembryonic antigen; Follow-up; Lung cancer; Surveillance

Mesh:

Substances:

Year:  2013        PMID: 23979987     DOI: 10.1093/ejcts/ezt424

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.

Authors:  Sinead A Noonan; Tejas Patil; Dexiang Gao; Gentry G King; Jessica R Thibault; Xian Lu; Paul A Bunn; Robert C Doebele; W Thomas Purcell; Anna E Barón; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2017-08-24       Impact factor: 15.609

2.  Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer.

Authors:  Ximing Wang; Na Song; Ye Zhang; Ying Cai; Yunpeng Liu; Xiujuan Qu; Zhi Li; Danni Li; Kezuo Hou; Jian Kang; Xuejun Hu
Journal:  Tumour Biol       Date:  2015-04-14

3.  The ABO blood group is an independent prognostic factor in patients with resected non-small cell lung cancer.

Authors:  Koichi Fukumoto; Tetsuo Taniguchi; Noriyasu Usami; Koji Kawaguchi; Takayuki Fukui; Futoshi Ishiguro; Shota Nakamura; Kohei Yokoi
Journal:  J Epidemiol       Date:  2014-12-06       Impact factor: 3.211

4.  Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report.

Authors:  Hiroaki Komatsu; Nobuhiro Izumi; Takuma Tsukioka; Michihito Toda; Kantaro Hara; Hikaru Miyamoto; Noritoshi Nishiyama
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-12-15       Impact factor: 1.520

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.